GC Corp.'s Form 4 filing
Artiva Biotherapeutics, Inc. (ARTV) · filed May 28, 2026
- Accession no.
- 0001931382-26-000007
- Filed
- May 28, 2026, 4:34 PM ET
- Trade date
- May 11, 2026
- Filing delay
- 17 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $16.5M. It was filed 17 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| GC Corp.CIK 0001931382 | 10% Owner |
| GC Cell CorpCIK 0001931891 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Common Stock | PPurchaseAcquired | +1,085,069 | $11.52 | +$12,499,994.88 | 4,391,969 | Direct | |
| May 11, 2026 | Common Stock | PPurchaseAcquired | +347,222 | $11.52 | +$3,999,997.44 | 1,607,734 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.